Navigation Links
Alexza to Present at the MDB Bright Lights Conference 2011
Date:5/6/2011

ped for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted the AZ-004 NDA in December 2009.  In October 2010, the Company received a Complete Response Letter, or CRL, from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company completed an end-of-review meeting with the FDA in late December 2010.

The Company believes it has a clear understanding of the issues outlined in the CRL, is developing and executing a plan to address these issues, and currently projects a resubmission of the AZ-004 NDA in July 2011.

For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's current operations, the potential of the Company's planned AZ-004 NDA resubmission to adequately address the issues in the CRL, the eventual prospects that AZ-004 will be approved for marketing and the timing of the Company's resubmission of the AZ-004 NDA to the FDA.  The Company's forward-looking statements also involve assumptions tha
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has ... Market by Product, Application, Technology, End User - Global ... The infectious disease diagnostics market is expected ... million by 2019 from $12,422.8 million in 2014. Increase ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... YORK, Dec. 21 Intra-Cellular Therapies, Inc. (ITI) announced ... from a recently completed Phase I clinical study demonstrating ... targets in the living human brain. These key ... and related disorders. Using positron emission tomography (PET) ...
... , , , BEIJING, Dec. 21 ... biopharmaceutical products in China, announced today,that Sinovac was selected by ... companies listed overseas for 2009. The honor was given to,Sinovac ... The "Competitiveness Measure" is the measuring ...
Cached Medicine Technology:Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders 2Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders 3Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders 4Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders 5Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009 2Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009 3
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who ... are thrilled to have it lead the wedding dress industry ... of prom dresses for the global market. , “The CEO ... and he focuses on continuing the goal of operational excellence ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... patch promises to alleviate symptoms of early-stage Parkinson's disease, ... pills to manage the brain disorder,// researchers said., ... pharmaceutical was used to study its effects on 277 ... Parkinson's. The patch is designed to convey a ...
... heavily over a short period of time or drink continuously ... face more depression than men, says a study.// ... Medicine and Health Sciences and other researchers studied the alcohol ... of depression, according to the online edition of BBC News. ...
... acid, a vital B vitamin is a must in the medicine ... of folic acid could lead to serious birth defects// in the ... stroke and heart disease. Now, there appears to be one more ... Folic acid may actually reduce low frequency hearing loss, researchers said. ...
... sons, may have a greater risk of getting prostate cancer, ... compared families of men diagnosed with prostate cancer with other ... prostate cancer were related. ,The Journal of the ... but the factors responsible for prostate cancer and having more ...
... the number of influenza cases over the last four months ... statistics released by the Public// Health Agency on Dec 16. ... March or early April and the Calgary Health Region monitors ... A are; sudden headaches and fever, dry coughs and aching ...
... based on the data put together in health maps, show ... 10 unhealthiest places.// ,Valley areas have held such ... soon overtake them. ,Poor diet and a growing ... the post-industrial traumas seen there, and this may put more ...
Cached Medicine News:Health News:Gender Of Children May Be Linked To Risk Of Prostate Cancer 2Health News:Lifestyles Cause Concern To Welsh Health Officials 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: